Hualan vaccine (301207.SZ): Clinical trials of the novel influenza virus mRNA vaccine have been approved. Currently, no influenza virus mRNA vaccine products have been approved for marketing in China

According to the Zhitong Finance App, Hualan Vaccine (301207.SZ) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” for the novel influenza virus mRNA vaccine approved and issued by the State Drug Administration. The novel influenza virus mRNA vaccine developed by the company uses mRNA technology routes to express the corresponding antigen in the body and induce an immune response in the body by delivering mRNA coding for influenza virus-related antigens. According to public research data, mRNA vaccine technology has the characteristics of flexible antigen design, relatively short design and production cycle, etc., and has certain technical application potential in dealing with influenza virus antigen variants and vaccine strain updates.

As of the disclosure date of this announcement, according to public information, no influenza virus mRNA vaccine products have been officially approved for marketing in China, and there is no public information that other influenza virus mRNA vaccine products have obtained drug clinical trial approval; in foreign countries, influenza virus mRNA vaccine products developed by Modner have been approved for marketing by the US Food and Drug Administration (FDA) in August 2026; products related to influenza virus mRNA vaccine developed by GlaxoSmithKline and Pfizer are all in clinical trials.